Figure 1From: Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injuryPersistence of hASCs and mASCs and change in body weight. (a) The percentages of total injected hASCs or mASCs present in the lung 20 hours after oropharyngeal administration for PBS-and LPS-challenged mice. Real-time RT-PCR analysis using human GADPH and eGFP primers was used to track and quantify the hASCs and mASCs, respectively. N = 4, 4, 4, and 5 for PBS + hASC, PBS + mASC, LPS + hASC, and LPS + mASC, respectively. (b) Changes in body weight following treatment with HBSS, hASC, or mASC were compared 24 hours after PBS or LPS challenge. N = 7, 6, 6, 16, 10, and 10 for Intact, PBS + hASC, PBS + mASC, LPS + HBSS, LPS + hASC, and LPS + mASC, respectively. Significance was defined as *** for P <0.001, for comparison of the experimental cell treatment groups to the HBSS-treated LPS-challenged mice. eGFP, enhanced green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hASCs, human adipose-derived stem cells; HBSS, Hank's balanced salt solution; LPS, lipopolysaccharide; mASCs, mouse adipose-derived stem cells; PBS, phosphate-buffered saline; RT-PCR, reverse transcription-polymerase chain reaction.Back to article page